Welcome to our dedicated page for Dogwood Therapeutics SEC filings (Ticker: DWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dogwood Therapeutics filings document the regulatory record of a Delaware development-stage biopharmaceutical company focused on pain and neuropathy medicines. Its 8-K reports include financial results, Regulation FD shareholder letters, corporate updates, and material-event disclosures tied to the Halneuron® and SP16 IV development programs.
Proxy and meeting filings cover stockholder voting matters, governance, executive compensation, equity incentive plans, and Nasdaq-related approvals for warrant exercises and common stock issuances. The filing record also documents capital-structure matters, securities purchase agreements, equity awards, and risk-oriented disclosures associated with a clinical-stage biotechnology issuer.
Dogwood Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2026 and remains a pre-revenue, development-stage biopharmaceutical company focused on cancer-related pain and chemotherapy-induced neuropathy.
The company posted a net loss of $11.5 million for the quarter and $16.5 million for the first half of 2026, driven by $3.2 million in research and development, $1.6 million in general and administrative expenses, and a $9.2 million IPR&D impairment in the quarter. A net non-cash IPR&D impairment charge of $6.7 million was recognized after a related deferred tax benefit.
Cash and cash equivalents increased to $9.6 million as of June 30, 2026, helped by $11.4 million of net proceeds from a January 2026 equity offering, but operating activities used $8.2 million of cash in the first half. Accumulated deficit reached $124.6 million and management disclosed substantial doubt about the company’s ability to continue as a going concern beyond the fourth quarter of 2026 without additional financing.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Dogwood Therapeutics, Inc. common stock. They collectively report 3,384,798 shares, representing 9.99% of the class, with shared power to vote and dispose of all reported shares and no sole voting or dispositive power.
The shares are held directly by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company for which Armistice Capital serves as investment manager under an Investment Management Agreement. Through this role, Armistice Capital and Mr. Boyd may be deemed to beneficially own the shares, while the Master Fund has the economic right to dividends and sale proceeds and disclaims beneficial ownership due to its lack of voting and dispositive power.
Dogwood Therapeutics, Inc. reported second quarter 2026 results with no revenue and a focus on advancing its non-opioid pain pipeline. The Halneuron® Phase 2b trial in chemotherapy-induced neuropathic pain is on track for top-line data in fall 2026, with 217 patients enrolled and plans to enroll over 220 patients to provide more than 80% statistical power.
For the quarter ended June 30, 2026, research and development expenses were $3.25 million and general and administrative expenses were $1.63 million. Dogwood recorded a non-cash IPR&D impairment charge of $9.19 million, leading to a net loss attributable to common stockholders of $11.53 million, or $0.34 per share. Cash was $9.61 million as of June 30, 2026.
Strategically, Dogwood highlighted a worldwide development and commercialization partnership for legacy antiviral assets with potential value of up to $100 million for the company and its CVR holders, the start of a Phase 2b long-term extension study of Halneuron®, and a fully National Cancer Institute–funded forthcoming SP16 IV Phase 1b trial.
Dogwood Therapeutics, Inc. held its annual stockholder meeting, where investors approved an amendment to the Certificate of Incorporation to increase the number of authorized common and preferred shares. Stockholders also elected seven directors, ratified Forvis Mazars, LLP as auditor for 2026, and endorsed executive pay.
Holders of 31,791,500 common shares, representing 95.17% of the voting power as of the record date, were present in person or by proxy, providing a strong quorum. Stockholders supported holding advisory votes on executive compensation every year, and the Board agreed to include this annual vote in future proxy materials.
Dogwood Therapeutics, Inc. director Abel De La Rosa received a grant of stock options, giving the right to buy 16,800 shares of common stock. The options have an exercise price of $1.50 per share and were awarded at no cost as equity compensation.
After this grant, De La Rosa holds stock options for 16,800 underlying shares directly. The options become exercisable starting on June 16, 2027 and expire on June 16, 2036, providing long-term potential ownership if exercised in the future.
Thomas John C reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics director Thomas John C received a grant of stock options giving him the right to buy 16,800 shares of common stock at $1.50 per share. These options expire on June 16, 2036 and are held directly, with 16,800 derivative securities reported following the grant. This is a compensation-related award rather than an open-market purchase or sale.
Dogwood Therapeutics director Richard James Whitley received a grant of stock options for 16,800 shares of Common Stock. The options carry an exercise price of $1.50 per share, become exercisable on June 16, 2027, and expire on June 16, 2036. Following this award, he holds 16,800 derivative securities directly.
Dogwood Therapeutics director David R. Keefer received a new stock option grant for 16,800 shares of common stock. The options have an exercise price of $1.50 per share, allowing him to buy shares at that price in the future. Following this grant, he holds 16,800 options directly. The options become exercisable starting June 16, 2027 and expire on June 16, 2036, making this a long-term, compensation-related award rather than an open-market trade.
Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 3,343,120 shares of Dogwood Therapeutics, Inc. common stock, representing 9.99% of the class. The filing states shared voting and dispositive power over those shares and identifies Armistice Capital as investment manager for the Master Fund. The joint filing is signed by Steven Boyd on 05/15/2026.
Dogwood Therapeutics, Inc. filed its Form 10-Q reporting first-quarter 2026 results as a pre-revenue, development-stage biopharmaceutical company focused on cancer pain and neuropathy. The company posted a net loss of $4,986,614 for the three months ended March 31, 2026, narrowing from $10,924,952 a year earlier, as total operating expenses were $5,076,366.
Cash and cash equivalents increased to $13,227,839 at March 31, 2026 from $6,524,744 at year-end 2025, helped by net proceeds of about $11.4M from a January 2026 equity and warrant financing. The accumulated deficit reached $113,062,930, and management states that existing cash will not fund operations for at least 12 months, indicating substantial doubt about the company’s ability to continue as a going concern without additional financing.